The treatment with 2-SC 163 at low and high dose (3 mg/kg and 6 mg/kg, respectively) significantly decreased the level of cyclin D1 in the tumor, whereas it increased the level of GSK-3β, when compared to the untreated group. The gene discussed is CCND1; the disease is neoplasm.